Tony Keating, CEO and Managing Director said: “We are delighted to have secured FDA clearance for SleepCheckRx. With more than 20 million American adults suffering from sleep apnoea and the majority of those not knowing that they have the condition, this clearance unlocks a significant market opportunity for ResApp. By using SleepCheckRx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnoea, helping their patients take the first step to getting treatment.” #
Investors are seriously missing the importance of sleep check FDA and Medgate renewal Ann. We have focused too much on SP no movement and the T/O.
Last quarterly we received 178k from Sleepcheck download, DX use in Switzerland and Jassen down payment.
Sleep check FDA has opened the US 20m ppl market and will help its global marketing and sales. To say in 6 months time the download income will be 10times from last qtr is an underestimate.
Medgate as a major telehealth player in Switzerland, happily expanded into Germany. They will surely self market into other Eu territory, again there’s 10 times more revenue in 6 month time compared to this Jan- March
Alodoktor is a major platform in Indonesia, along with doctor in demand launched in Jan, they will cover hundreds of millions of users given time, I am expecting great performance similar to Medgate use with good income to be shown soon.
Homily will launch mid of calendar year 2022 in Philippine, another big population country cracked.
From these sources, revenue growth will be 10 folds without spiking cost at all. In other words, if Covid screen tool is separately sold to Pfizer, the rest of RAP will generate 8-10m revenue per year easily to fly SP north of 27.7cents, let alone Resapp DX can get FDA clearance before this Xmas, worked out from sleep check FDA timeline.
I hope this can answer why SP won’t fall back to 5cents if Pfizer walk away. They better go away as quick as they can.
Last point, the scheme meeting will need to include official IE report for SH to judge whether it’s in their best interest or not. BDO is fully aware of this, as required by ASIC, that they cannot ignore the 2 huge Ann’s in the run, it maybe coming out as early as next week, or the week after. All IMO
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx, page-115
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)